Investment Highlights

With new and unique technologies and active substances, the biopharmaceutical company MOLOGEN is one of the pioneers in the field of immunotherapy. Alongside a focus on immuno-oncology, MOLOGEN also develops immunotherapies for the treatment of infectious diseases.

What sets us apart:

  • Biopharmaceutical company developing ground-breaking immunotherapies
  • Lead product lefitolimod (MGN1703): potential blockbuster candidate
  • Targeting indications with high unmet medical needs: Cancer and HIV
  • Attractive for partnering/licensing: Advanced, close-to-market product candidate with long-term exclusivity and promising next generation successor molecules

• Three-month exclusivity period for negotiations with ONCOLOGIE on the global assignment of lefitolimod expired without agreement • During the exclusivity period ONCOLOGIE presented new financial terms for the transaction that were vastly inferior to those agreed in the non-binding term sheet signed by the two companies on August 15th, 2018;... [more]

Annual Report 2017

Download pdf

Quarterly Statement as at 31 March 2018

Download pdf

Half-Yearly Financial Statement as at 30 June 2018

Download pdf

Quarterly Statement as at 30 September 2018

Download pdf

November 8, 2018

Quarterly Statement as of September 30, 2018

 

Show complete Corporate Calendar.

19 October - 23 October 2018

ESMO Congress 2018, Munich, Germany

 

25 September 2018

Berenberg & Goldman Sachs 7th German Corporate Conference, Munich, Germany

 

 


Show complete calendar.

 

 

 

 

Share Price

Contact:

Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Phone: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50
investor@mologen.com

Distribution list

If you would like to receive our press releases, please click here.